Stool-Based DNA Test Detects 92% of Colorectal Cancers
Exact Sciences announced the results of its DeeP-C clinical study comparing the efficacy of Cologuard, a multi-target stool DNA-based screening test, to the fecal immunochemical test.
The study found:
• Cologuard detected 92 percent of colorectal cancer, compared to 74 percent in FIT
• Cologuard detected 93 percent of colorectal cancers in Stages I-III, while FIT detected 73 percent
• Cologuard demonstrated a 42 percent sensitivity level in patients with advanced precancerous lesions, while FIT demonstrated 24 percent sensitivity
• Cologuard detected 69 percent of patients with high-grade dysplasia polyps, while FIT detected 46 percent
• Cologuard had a specificity of 87 percent, while FIT had specificity of 95 percent
The results of the study were published in the New England Journal of Medicine.
More Articles on Gastroenterology:
ACG Partners With National Colorectal Cancer Roundtable to Works Toward '80 by 2018' Goal
28 Statistics on Colonoscopy Indications
10-Year Stretta Outcomes for GERD Treatment: Q&A With Dr. Mark Noar
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
New from Becker's ASC Review